338 related articles for article (PubMed ID: 36387176)
1. Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer.
Fang X; Yu S; Jiang Y; Xiang Y; Lu K
Front Oncol; 2022; 12():1027664. PubMed ID: 36387176
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
3. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
4. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
Peng Y; Mei W; Ma K; Zeng C
Front Oncol; 2021; 11():763790. PubMed ID: 34868984
[TBL] [Abstract][Full Text] [Related]
5. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
[No Abstract] [Full Text] [Related]
6. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
[TBL] [Abstract][Full Text] [Related]
7. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
8. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer.
Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C
Transl Res; 2024 Jun; 272():41-53. PubMed ID: 38838851
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review.
Zhu L; Xu R; Yang L; Shi W; Zhang Y; Liu J; Li X; Zhou J; Bing P
Front Genet; 2023; 14():1172108. PubMed ID: 37636270
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
11. Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review.
Verzè M; Pluchino M; Leonetti A; Corianò M; Bonatti F; Armillotta MP; Perrone F; Casali M; Minari R; Tiseo M
Transl Lung Cancer Res; 2022 Dec; 11(12):2588-2600. PubMed ID: 36636413
[TBL] [Abstract][Full Text] [Related]
12. Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer.
Yang J; Hui Y; Zhang Y; Zhang M; Ji B; Tian G; Guo Y; Tang M; Li L; Guo B; Ma T
Front Oncol; 2021; 11():725938. PubMed ID: 34422670
[TBL] [Abstract][Full Text] [Related]
13. PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.
Xu J; Pu Y; Lin R; Xiao S; Fu Y; Wang T
Front Med (Lausanne); 2022; 9():822200. PubMed ID: 35308511
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives.
Zografos E; Dimitrakopoulos FI; Koutras A
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230877
[TBL] [Abstract][Full Text] [Related]
15. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions.
O'Sullivan HM; Feber A; Popat S
Onco Targets Ther; 2023; 16():249-259. PubMed ID: 37056631
[TBL] [Abstract][Full Text] [Related]
17. Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer--A retrospective study of ctDNA.
Zhang X; Zhang Y; Zhang S; Wang S; Yang P; Liu C
Front Oncol; 2023; 13():1098128. PubMed ID: 37091156
[TBL] [Abstract][Full Text] [Related]
18. Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.
Larribère L; Martens UM
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830853
[TBL] [Abstract][Full Text] [Related]
19. [Application Value of ctDNA-based MRD Dedection
in Early Stage Non-small Cell Lung Cancer after Radical Surgery].
Dou S; Xie H; Yang L
Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):862-866. PubMed ID: 34743498
[TBL] [Abstract][Full Text] [Related]
20. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
Chae YK; Oh MS
J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]